Transporter proteins from the MATE (multidrug and toxic compound extrusion) 1 family are vital in metabolite transport in plants 2, 3 , directly affecting crop yields worldwide 4 . MATE transporters also mediate multiple-drug resistance (MDR) in bacteria and mammals 5 , modulating the efficacy of many pharmaceutical drugs used in the treatment of a variety of diseases [6] [7] [8] [9] . MATE transporters couple substrate transport to electrochemical gradients and are the only remaining class of MDR transporters whose structure has not been determined 10 . Here we report the X-ray structure of the MATE transporter NorM from Vibrio cholerae determined to 3.65 Å, revealing an outward-facing conformation with two portals open to the outer leaflet of the membrane and a unique topology of the predicted 12 transmembrane helices distinct from any other known MDR transporter. We also report a cation-binding site in close proximity to residues previously deemed critical for transport 11 . This conformation probably represents a stage of the transport cycle with high affinity for monovalent cations and low affinity for substrates.
Cellular export of toxins and substrates is a fundamental life process, and members of the MATE family are the last class of MDR transporters to be structurally characterized. MATE transporters are involved in a variety of important biological functions across all kingdoms of life. In plants, MATE transporters are highly prevalent, with 58 paralogues found in Arabidopsis thaliana 12 , and they secrete a diverse range of secondary metabolites as a defence against herbivores and microbial pathogens 3, 5 . In addition, plant MATE transporters are important in tolerance towards phytotoxic aluminium in acidic soils, a major limitation of crop production in 50% of the world's arable land 4 . In mammals they export a structurally diverse array of xenobiotic cations in the liver and kidney, influencing the plasma concentrations of many drugs, including metformin, a widely prescribed type 2 diabetes medication, thereby mitigating therapeutic efficacy 8, 9 . Bacterial MATE transporters function primarily as xenobiotic efflux pumps and can confer resistance to tigecycline, a new glycylcycline-class antibiotic developed to overcome methicillin-resistant and vancomycin-resistant Staphylococcus aureus 6, 7 . MATE transporters use either H 1 or Na 1 gradients across the membrane to drive substrate export, although the coupling mechanism is not well understood. All MATE proteins share about 40% protein sequence similarity 5 ( Supplementary Fig. 1a ), suggesting an overall conserved structure and transport function. To provide a basis for understanding the function of MATE transporters, we present two X-ray structures ( Fig. 1) of NorM from V. cholerae (NorM-VC) with and without rubidium (Rb 1 ), using protein purified in n-dodecyl-b-D-maltopyranoside, and crystallized with n-nonyl-b-glucopyranoside (b-NG) and a novel facial amphiphile 13 , 3a-hydroxy-7a,12a-bis[(b-D-maltopyranosyl)ethyloxy] cholane (FA-231) as additives (see Methods). Although nearly identical, the structure of apo-NorM-VC was solved to a higher resolution at 3.65 Å. The structure reveals a novel topology distinct from all other MDR transporter families [14] [15] [16] [17] [18] . This outward-facing conformation also presents a monovalent cation-binding site within the internal cavity. NorM-VC retains transport activity in Escherichia coli ( Supplementary  Fig. 2 ), and purified NorM-VC protein binds MATE substrates 5 (Supplementary Fig. 3 and Supplementary Table 1 ).
The structure of NorM-VC spans about 50 Å in the plane of the lipid bilayer and is arranged as two bundles of six transmembrane helices (TM1-TM6 and TM7-TM12) forming a large internal cavity open to the extracellular space (Fig. 1) . The two halves are related by an intramolecular two-fold symmetry, probably a result of gene duplication as reflected within its primary sequence. A cytoplasmic loop (residues 218-232 between TM6 and TM7) connects the two halves, as also seen in transporters of the major facilitator superfamily (MFS) [18] [19] [20] , whereas the initial helix of each half (TM1 and TM7) is preceded by a helical extension (residues 2-18 and 233-247) from the inner membrane leaflet side. An additional helix (residues 450-461) after TM12 is nestled under the cytoplasmic side of TM11. The model was obtained as described in Supplementary Information (Supplementary Fig. 4 Table 3) . Two structurally similar NorM-VC molecules (NorM1 and NorM2) constitute the asymmetric unit, allowing independent verification of the position and identity for each mercury-labelled cysteine residue (Supplementary Fig. 8 ).
The topology of NorM-VC is unique among all known transporters, and unlike other 12 transmembrane transporters such as those of the MFS, no transmembrane helices intersect the space defined by any cluster of three consecutive helices within each bundle (Fig. 2c, d ). For example, in the MFS, TM1 intersects TM4-TM6. Similarly, TM7 intersects TM10-TM12. No such helical arrangement is seen in NorM. Two non-equivalent portals, formed by TM1 and TM8 on one side and TM2 and TM7 on the other, open within the lipid bilayer, allowing the expulsion of substrates directly to the outer membrane leaflet or the extracellular space ( Fig. 3 and Supplementary Fig. 9 ). Within the lipid bilayer, the portals are a maximum of about 12 Å wide, sufficient to accommodate substrate passage. The volume of the internal cavity embedded within the lipid bilayer is about 4,300 Å 3 ( Supplementary  Fig. 10 ), about four times larger than the binding pockets of the transcription MDR regulators xPXR and BmrR 21, 22 , and nearly two-thirds that of the ABC exporters Pgp or MsbA 14, 16 . Residues facing the internal cavity are both relatively conserved and contributed by all transmembrane helices except for TM3 and TM9, which are located at the periphery in this conformation ( Fig. 1 and Supplementary Fig. 11 ). Of the 91 residues facing the cavity, 57 are hydrophobic, 14 are aromatic, 20 are polar and 5 are charged. Nine aromatic residues are clustered in the carboxy-terminal half of the internal cavity (Supplementary Table 4 ).
In the internal cavity we observed the binding of Rb 1 and also caesium (Cs 1 ) ions, which are heavier alkali-metal analogues of sodium more easily revealed by X-ray crystallography (Fig. 4a, b ) (see Methods). The cation-binding site of NorM-VC is composed of residues from TM7, TM8 and TM10-TM12 (Supplementary Table 4 ), a fundamentally different topology from that found in members of the MFS (Fig. 2c, d ). Previous studies have identified three conserved acidic residues that are critical for transport function in NorM from Vibrio parahaemolyticus (NorM-VP) 11 , a closely related orthologue of NorM-VC with 76% sequence identity and 86% similarity 23, 24 . These residues correspond to D36, E255 and D371 in NorM-VC (D32, E251 and D367 in NorM-VP). In our Rb 1 -bound NorM-VC structure, residues E255 and D371 face the internal cavity on the C-terminal half of the molecule and are located near the cation (Fig. 4) . For NorM-VP, both of these negatively charged residues are important for transport function, because certain mutations at these positions decouple substrate/Na 1 antiport
11
. As in NorM-VP, mutations at residue 255 in NorM-VC affect protein folding and do not express well 11 . Substitution mutations at D371 to alanine or asparagine abolish the binding of Rb 1 and Cs 1 in the outward-facing conformation ( Supplementary Fig. 12 ). These findings suggest that these and possibly other surrounding residues are crucial for the recognition and binding of cations from the extracellular space. Mutations of D367 in NorM-VP (D371 in NorM-VC) disrupt transport activity, further suggesting that cation binding at this site is important in the transport cycle 11 . In our outward-facing NorM-VC structure, residue D36 (D32 in NorM-VP) is located in the amino-terminal half, far from the C-terminal cationbinding site. We did not observe the presence of either Rb 1 or Cs 1 near D36 and speculate that this residue may be important in other conformations.
We propose that the outward-facing conformation of NorM-VC, like other efflux pumps 25, 26 , represents a state in the transport cycle that has high affinity for monovalent cations (Fig. 4c , step 1), and a lower affinity for substrates. Although the internal cavity is accessible to mercury compounds (Fig. 2a, b and Supplementary Fig. 7 ), this conformation is not amenable to co-crystallization or soaking with several well-established drugs or transport substrates. We propose that, on binding of cations, NorM-VC undergoes an outward-facing to inward-facing conformational change that is more favourable to substrate binding (Fig. 4c, step 2) . In this conformation, cation release and/or substrate binding could induce a structural change back to the outward-facing conformation 25, 26 , in which the substrate is released into the outer leaflet of the lipid bilayer and/or extracellular space (Fig. 4c, step 3) .
The structure of NorM reveals the last known MDR transporter family revealed by X-ray crystallography. Unlike the RND (resistance, nodulation and cell-division) transporter family, in which an extracellular domain mediates substrate binding, MATE transporters alongside MDR transporters from the ABC, MFS and SMR (small multidrug resistance transporter family) families have poly-specific drug-binding sites composed of transmembrane helices within the lipid bilayer [14] [15] [16] 18 . Despite wide primary sequence divergence, the extraction and expulsion of substrates directly from the inner to the outer membrane leaflet through portals facing the lipid bilayer (Fig. 4c ) may be a common theme for these transporter families. The shared V-shaped conformations among them suggest that this may be so, providing a molecular basis for hydrophobic/amphipathic substrate transport.
METHODS SUMMARY
Crystallization and structure determination. NorM-VC protein was recombinantly expressed in E. coli BL21 DE3 by using pET19b, solubilized with n-dodecylb-D-maltopyranoside, and purified by Ni 21 -affinity chromatography. Crystals were grown by the sitting-drop method in buffer containing 2 H 2 O with TrisHCl, (NH 4 ) 2 SO 4 , polyethylene glycol 250 dimethyl ether (PEG 250DME), 0.23% b-NG and 0.02% FA-231. Wild-type and mutant crystals were derivatized by mercury compounds dissolved in mother liquor. Diffraction data were processed with the programs HKL2000 and MOSFLM. Protein phasing, model building and crystallographic refinement were achieved with the programs PHASES, SOLVE/ RESOLVE and CNS v. 1.2. To verify the identity and position of certain residues as well as characterizing the cation-binding site, NorM-VC wild-type and mutant crystals were soaked with the appropriate compounds and diffraction data were collected. Isomorphous difference Fourier maps, calculated from suitable pairs of data sets, were calculated with CNS v. 1.2 and confirmed the mercury labelling of cysteine residues and the binding of Rb 1 or Cs 1 to the cation-binding site. Supplementary Fig. 1b . c, Extracellular view, with helices TM1-TM12 marked. The internal cavity opens to the extracellular space and is occluded on the cytoplasmic side. The molecule is coloured using a rainbow gradient from the N terminus (blue) to the C terminus (red). is indicated. In MATE transporters, TM1 is between TM5 and TM8, and TM7 is between TM3 and TM11. The portals facing the membrane are formed between TM1 and TM8 and between TM2 and TM7. In contrast, the MFS has TM1 between TM4, TM5 and TM6. Similarly, TM7 is between TM10, TM11 and TM12. d, X-ray structures of NorM (left) and the MFS transporter EmrD (right) 18 . Supplementary Fig. 12 . c, Proposed transport mechanism. In the outward-facing conformation, a cation (yellow) binds at a conserved site (blue oval; step 1). Cation binding induces structural changes to the inward-facing conformation (step 2), which is competent to bind substrate (organic cation in green) from the inner membrane leaflet or cytoplasm. Substrate binding causes structural changes back to the outward-facing conformation (step 3), allowing export and cation binding.
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RESEARCH LETTER METHODS
Cloning, mutagenesis, protein expression, and purification. NorM (NCBI accession number AE003852.1, region 1652328-1653713) was cloned from Vibrio cholerae genomic DNA (ATCC 39315) into the expression vector pET19b (Novagen) between the NdeI and XhoI restriction sites of the multiple cloning site. The pET19b vector bears an N-terminal His 10 tag followed by an enterokinase cleavage site upstream of the multiple cloning sites. Single cysteine substitution mutants for structure and topology verification were generated from the pET19b-norM-VC construct using the QuickChange Site-directed Mutagenesis Kit (Stratagene), in accordance with the protocol from the manufacturer. Cloning and mutagenesis primers were likewise designed in accordance with the manufacturer's instructions and synthesized by Integrated DNA Technologies. PET19b-norM-VC plasmid was transformed into, and expressed in, Escherichia coli BL21 DE3 (Invitrogen) as 100-litre batches grown in a bioreactor (BioFlow 5000; New Brunswick Scientific) from an initial 1-litre seed culture. Cells were grown to an attenuance at 600 nm (D 600 ) of 0.550 at 37 uC and induced with 0. . The N-terminal His 10 tag was removed by digestion with enterokinase (New England Biolabs) in the manufacturer's recommended buffer for 12 h at 16 uC at a protein-to-enzyme-stock ratio of 25:1 (v/v). After digestion, the free His 10 tag was removed by Ni 21 -affinity chromatography; the tag-free NorM-VC protein was concentrated to 40 mg ml 21 and then ultracentrifuged at 323,400g at 4 uC for 55 min. Protein purity was evaluated by SDS-PAGE and the concentration was determined by spectrophotometry at A 280 using a molar absorption coefficient, e 280 , of 56.4 3 10 23 M 21 cm
21
. Purification of the mutants followed an identical protocol. Crystallization of NorM-VC. Crystals of NorM-VC were grown from b-DDMsolubilized protein and 0.23% b-NG with the following range of conditions: 50 mM Tris-HCl pH 7.2-8.6, 87 mM (NH 4 ) 2 SO 4 , 16-24% PEG 250DME (Omega Scientific) in 2 H 2 O (Cambridge Isotope Laboratories). Crystals were grown by the sitting-drop method from protein samples in a concentration range of 6-12 mg ml 21 at 22 uC, with a protein-to-precipitant ratio of 1:1 (v/v) in a 4-ml drop. The crystals appeared after three to four days, reaching peak size within a week. All single-site-substitution cysteine mutants were crystallized in this manner (Supplementary Table 3 ). We discovered that the addition of a novel facial amphiphile, FA-231 (ref. 13) , to the crystallization conditions improved the reproducibility of the crystals, lowering background precipitation. Both our highest-diffracting crystal, crystal 1 (3.65 Å; a 5 142. Table 2 ). In addition, the two cation-site mutants, D371A and D371N, were also crystallized in the presence of the facial amphiphile (Supplementary Table 3 ). We attribute the higher diffraction quality of crystal 1 mostly to serendipity, because there was a wide dependence of crystal growth on preparation. Derivatization and cryoprotection. Derivatization of native and single cysteine mutant crystals for phasing and structure verification was accomplished by soaking with either 5 mM mercury(II) acetate (Hg(OAc) 2 ), 5 mM mercury(II) cyanide (Hg(CN) 2 ) or 5 mM Bakers dimercurial (BDM), in fresh mother liquor made with 24% PEG 250DME and supplemented with 0.009% b-NG, with 0.016% b-DDM as cryoprotectant for periods ranging between 30 min and 1 h. Rubidium and caesium derivatization of native and cation-binding-site mutant crystals (D371A and D371N) was achieved by soaking with 200 mM RbCl or 200 mM CsCl, in mother liquor described above. RbCl, CsCl and 100 mM NaCl (used as a control) soaks all elicited rapid crystal degradation and precluded cation derivatization beyond 1 min, probably due to disruption of lattice contacts as a result of protein conformational changes. Data acquisition and structure determination. The initial experimental electron density map and structure of NorM-VC was determined by multiple anomalous dispersion (MAD) phasing and phase combination of three data sets: a DT130C crystal derivatized with Hg(OAc) 2 , and two native crystals soaked with Hg(CN) 2 and BDM, respectively (Supplementary Table 2 ). Protein phasing, solvent flattening, non-crystallographic symmetry (NCS) averaging, and phase extension were performed with the programs PHASES, SOLVE/RESOLVE and CNS v. 1.2 (refs 27-31). Overall combined phasing power was 1.7, with a figure of merit of 0.779 and an initial NCS averaging correlation coefficient of 0.6. The experimental electron density maps revealed two molecules in the asymmetric unit (NorM1 and NorM2) ( Supplementary Fig. 4) .
To verify the topology and structure of NorM-VC, we generated 16 unique singlesite substitution mutants, each replacing a native residue with a cysteine. These single cysteine mutants were crystallized and derivatized as described above. Diffraction data were collected at cryogenic temperature at synchrotron sources as indicated (Supplementary Tables 2 and 3 ) and analysed by the processing programs HKL2000 and MOSFLM 32, 33 . The isomorphous difference Fourier synthesis for each mutant data set (Supplementary Table 3 ) was generated with the CNS v. 1.2 software suite 31 using the model from crystal 2 with the Rb 1 removed. For each of these calculations, model phases were generated by rigid-body refinement and gradient minimization using this model and the mutant data (Supplementary Table 3 ). For each mutant, two NCS-related isomorphous difference peaks corresponding to a mercury site were observed for each molecule in the asymmetric unit (NorM1 and NorM2), confirming the position and identity of each cysteine mutation (Fig. 2, Supplementary Figs 7 and  8 , and Supplementary Table 3) . A composite of all the isomorphous difference Fourier maps of all cysteine mutants ( Fig. 2 and Supplementary Fig. 7 ) was generated by real-space map transformation of each isomorphous difference map (Supplementary Fig. 8 ) to the coordinates of the model from crystal 2. The isomorphous difference Fourier maps showing the presence of Rb 1 or Cs 1 (Fig. 4a, b and Supplementary  Fig. 12 ), and their absence as a consequence of cation-binding mutations D371A and D371N ( Supplementary Fig. 12 ), were calculated in a similar fashion.
Crystallographic refinement using data from crystals 1 and 2 was accomplished by using the maximum-likelihood target with amplitudes (mlf) using CNS v. Table 2 ). Additional modelling restraints used during crystallographic refinement included hydrogen-binding constraints for all secondary structure elements and harmonic non-crystallographic constraints (150 kcal mol [34] [35] [36] . Stereo figures were generated with PyMOL and Adobe Photoshop 7.0. NorM-VC substrate-binding activity by fluorescence polarization. A fluorescencebased approach was used with well-known MATE substrates 5 to characterize the binding activity of purified detergent-solubilized NorM-VC as summarized (Supplementary Table 1 ). The procedure in these fluorescence polarization experiments was similar to that described previously 15 . The experiments were accomplished with a microplate-reader-equipped Beckman DTX 880 fluorimeter and Nunc 384-well plates. In brief, protein samples were serially twofold diluted into 20 ml of desalting buffer with the addition of 0.23% b-NG (Desalting-NG) to obtain conditions similar to those used for crystallization. Equal amounts of substrate were then added to each well. The reaction mixture was preincubated at 25 uC for 10 min and fluorescence was measured at the same temperature. All experiments were performed in at least duplicate and experiments with each substrate were repeated at least three times with protein samples from different preparations ( Supplementary Fig. 3 and Supplementary Table 1) .
Experimental polarization values were calculated from to the equation P 5 1000 3 (I v 2 GI h )/(I v 1 GI h ), where P is the polarization value in each well, I v is the fluorescence intensity polarized parallel to the excitation light and I h is the fluorescence intensity polarized perpendicularly. G equals 0.65 and is the intensity ratio of the vertical to horizontal components of emission when the sample is excited with horizontally polarized light: G 5 I hv /I hh . To determine the dissociation constant, K d , the experimental P values were plotted against the NorM-VC protein concentration and fitted to the equation for single-binding-site protein-substrate complex formation: y 5 P 0 1 (P max 2 P 0 )([NorM-VC]/([NorM-VC] 2 K d )), where P 0 is the minimum fluorescence polarization value of free substrate, P max is the maximum fluorescence polarization when all fluorescent molecules are bound in protein-substrate complex, and [NorM-VC] is the protein concentration in each well, with P 0 , P max , and K d treated as variable during the calculations to achieve the least fitting error. Experimental data were calculated and plotted in Excel. The nonlinear fitting of data was performed in Origin 7 (Origin Lab).
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